Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Clin Cancer Res. 2016 Dec 19;23(12):3084–3096. doi: 10.1158/1078-0432.CCR-16-2022

Figure 5. The combination of ACY-1215 and ibrutinib leads to statistically significant tumor growth delay compared to single agent treatment in a xenograft mouse model of lymphoma.

Figure 5

(A) SCID-beige mice were injected with LY10 107 in their flanks and treated with ACY-1215 50 mg/kg days 1-5, 8-12, 15-19, ibrutinib 3 mg/kg days 1-20, or the combination via the intraperitoneal route. (B) Mice were weighed every 3-4 days as a measurement for toxicity. (C) Tumor volume was measure over time as a function of treatment group (D) Kaplan-Meier Curve was calculated for the resistant control mice as compared to the parental control and treatment cohorts.